UroGen Pharma: Patient dosed in mitomycin-based UGN-103 trial for LG-IR-NMIBC

UroGen Pharma announced that the first patient was dosed in the Phase 3 clinical trial of investigational drug UGN-103 , mitomycin for intravesical solution in development for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer or LG-IR-NMIBC . UGN-103 is a next-generation novel mitomycin-based formulation. “Reaching this Phase 3 trial milestone for UGN-103 highlights our drive to innovate and bring forward cutting-edge treatments for low-grade intermediate-risk non-muscle invasive bladder cancer,” said Liz Barrett, President and Chief Executive Officer, UroGen. “UGN-103 represents a significant step forward, offering potential improvements in manufacturing, convenience, and cost. We are excited about the potential of this next-generation formulation and look forward to furthering its development to advance the care of patients.”